Enliven Therapeutics Stock (NASDAQ: ELVN)

Dernières nouvelles pour Enliven Therapeutics (NASDAQ:ELVN) Stock

Enliven Therapeutics

Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.

Enliven Therapeutics, Inc. - Common Stock

Enliven Therapeutics Inc

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Guggenheim cut TEGNA Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGNA#NYSE">TGNA</a>) price target from $22 to $21. Guggenheim analyst Curry Baker maintained a Buy rating. TEGNA shares closed at $16.93 on Tuesday. See how other analysts view <a href="https://www.benzinga.com/quote/TGNA/analyst-ratings">this stock</a>.</li>
<li>Stephens &amp; Co. raised the price target for MSC Industrial Direct Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSM#NYSE">MSM</a>) from $85 to $90. Stephens &amp; Co. analyst Tommy Moll maintained an Equal-Weight rating. MSC Industrial Direct shares closed at $90.32 on Tuesday. See how other analysts <a href="https://www.benzinga.com/quote/MSM/analyst-ratings">view this stock</a>.</li>
<li>UBS raised Altria Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MO#NYSE">MO</a>) price target from $47 to $59. UBS analyst Faham Baig upgraded the stock from Sell to Neutral. Altria Group shares closed at $58.14 on Tuesday. See how other analysts <a href="https://www.benzinga.com/quote/MO/analyst-ratings">view this stock</a>.</li>
<li>JP Morgan cut the price target for Centene Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) from $75 to $48. JP Morgan analyst John Stansel downgraded the stock from Overweight to Neutral. Centene shares closed at $56.65 on Tuesday. <a href="https://www.benzinga.com/quote/CNC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Jefferies raised the price target for Ross Stores, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) from $135 to $150. Jefferies analyst Corey Tarlowe upgraded the stock from Hold to Buy. Ross Stores shares closed at $129.97 on Tuesday. <a href="https://www.benzinga.com/quote/ROST/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JMP Securities raised Carvana Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) price target from $275 to $440. JMP Securities analyst Nicholas Jones maintained a Market Outperform rating. Carvana shares settled at $338.26 on Tuesday. <a href="https://www.benzinga.com/quote/CVNA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham increased Axos Financial, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AX#NYSE">AX</a>) price target from $88 to $92. Needham analyst Kyle Peterson maintained a Buy rating. Axos Financial shares closed at $78.32 on Tuesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. increased Enliven Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVN#NASDAQ">ELVN</a>) price target from $40 to $48. HC Wainwright &amp; Co. analyst Robert Burns maintained a Buy rating. Enliven Therapeutics shares closed at $19.65 on Tuesday.  <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird boosted the price target for Chipotle Mexican Grill, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>) from $58 to $62. Baird analyst David Tarantino maintained an Outperform rating. Chipotle shares settled at $58.24 on Tuesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird increased Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) price target from $635 to $740. Baird analyst Colin Sebastian maintained an Outperform rating. Meta shares closed at $719.22 on Tuesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying META stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/meta/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="611" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/02090254/image-28-1024x611.png" alt="" class="wp-image-970387" style="width:602px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/02090254/image-28-1024x611.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/02090254/image-28-300x179.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/02090254/image-28-768x458.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/02090254/image-28.png 1090w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/dividends/25/07/46216643/wall-streets-most-accurate-analysts-give-their-take-on-3-financial-stocks-delivering-high-dividend-yields-4">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Financial Stocks Delivering High-Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

News

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

CVNA

ELVN

ROST

TGNA

Meta To Rally Around 3%? Here Are 10 Top Analyst Forecasts For Wednesday

HC Wainwright &amp; Co. analyst Robert Burns maintains Enliven Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVN#NASDAQ">ELVN</a>) with a Buy and raises the price target from $40 to $48.

HC Wainwright & Co. Maintains Buy on Enliven Therapeutics, Raises Price Target to $48

Goldman Sachs analyst Salveen Richter initiates coverage on Enliven Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVN#NASDAQ">ELVN</a>) with a Buy rating and announces Price Target of $37.

Initiation

Goldman Sachs Initiates Coverage On Enliven Therapeutics with Buy Rating, Announces Price Target of $37

Baird analyst Colleen Kusy maintains Enliven Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVN#NASDAQ">ELVN</a>) with a Outperform and raises the price target from $40 to $52.

Baird Maintains Outperform on Enliven Therapeutics, Raises Price Target to $52

<h3>Gainers</h3>
<ul>
<li>Vaxart (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VXRT#NASDAQ">VXRT</a>) stock rose 35.9% to $0.73 during Friday's regular session. The company's market cap stands at $166.5 million. </li>
<li>Enliven Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVN#NASDAQ">ELVN</a>) shares increased by 16.78% to $22.96. The market value of their outstanding shares is at $1.1 billion. </li>
<li>Owlet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OWLT#NYSE">OWLT</a>) shares rose 14.53% to $7.41. The company's market cap stands at $122.4 million. </li>
<li>NexGel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXGL#NASDAQ">NXGL</a>) stock moved upwards by 13.58% to $2.51. The company's market cap stands at $19.2 million. </li>
<li>Tiziana Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLSA#NASDAQ">TLSA</a>) shares increased by 13.3% to $1.61. The market value of their outstanding shares is at $188.0 million. </li>
<li>SenesTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNES#NASDAQ">SNES</a>) shares increased by 13.21% to $3.17. The company's market cap stands at $5.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock decreased by 32.3% to $0.02 during Friday's regular session. The company's market cap stands at $8.2 million. </li>
<li>Know Labs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KNW#AMEX">KNW</a>) shares declined by 23.03% to $3.41. The company's market cap stands at $25.3 million. </li>
<li>Processa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) shares declined by 22.72% to $0.27. The company's market cap stands at $3.1 million. </li>
<li>Adial Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) stock declined by 20.83% to $0.36. The company's market cap stands at $2.8 million. </li>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) stock fell 19.35% to $0.12. </li>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) shares declined by 18.7% to $0.87. The company's market cap stands at $4.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ADIL

HCTI

NCNA

NXGL

OWLT

PCSA

PLRZ

SNES

TLSA

VXRT

12 Health Care Stocks Moving In Friday's Intraday Session

WIIM

Enliven Therapeutics shares are trading higher. The company announced the pricing of an underwritten public offering of 8.39 million hares at $19.66 per share.

Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVN#NASDAQ">ELVN</a>), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has priced its previously announced underwritten public offering of 8,394,737 shares of its common stock at a price to the public of $19.66 per share and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase up to 1,780,263 shares of Enliven's common stock at a price to the public of $19.659 per pre-funded warrant, which represents the per share public offering price of each share of Enliven's common stock less the $0.001 per share exercise price for each pre-funded warrant. All of the shares and pre-funded warrants are being sold by Enliven.&nbsp;
The gross proceeds from the offering are expected to be approximately $200 million before deducting underwriting discounts and commissions and other offering expenses.&nbsp;The offering is expected to close on or about June 16, 2025, subject to satisfaction of customary closing conditions. In addition, Enliven has granted the underwriters a 30-day option to purchase up to an additional 1,526,250 shares of its common stock at the public offering price, less the underwriting discounts and commissions.

Offerings

Enliven Therapeutics Prices Underwritten Public Offering Of 8.39M Shares At $19.66/Shr

Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVN#NASDAQ">ELVN</a>), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has commenced an underwritten public offering of $200 million of shares of its common stock and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase shares of Enliven's common stock. In addition, Enliven intends to grant the underwriters a 30-day option to purchase up to an additional $30 million of shares of its common stock. All of the shares of common stock and pre-funded warrants are being offered by Enliven. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Enliven Therapeutics Launches $200M Public Offering With Option For $30M Upsize

Reported cumulative MMR rate of 47% (25 of 53) by 24 weeks with 32% (13 of 41) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent Phase 1 trials of approved &nbsp;

Enliven Therapeutics Announced Updated Data From Phase 1 ENABLE Clinical Trial Evaluating ELVN-001 In Patients With Chronic Myeloid Leukemia In An Oral Presentation At European Hematology Association 2025 Congress

Jones Trading analyst Soumit Roy maintains Enliven Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVN#NASDAQ">ELVN</a>) with a Buy and lowers the price target from $36 to $27.

Jones Trading Maintains Buy on Enliven Therapeutics, Lowers Price Target to $27

Enliven Therapeutics shares are trading lower after the company reported worse-than-expected Q1 EPS results.

HC Wainwright &amp; Co. analyst Robert Burns maintains Enliven Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVN#NASDAQ">ELVN</a>) with a Buy and raises the price target from $39 to $40.

HC Wainwright & Co. Maintains Buy on Enliven Therapeutics, Raises Price Target to $40

Enliven Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVN#NASDAQ">ELVN</a>) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of $(0.49) by 16.33 percent. This is a 5.56 percent decrease over losses of $(0.54) per share from the same period last year.

Earnings

Earnings Misses

Enliven Therapeutics Q1 EPS $(0.57) Misses $(0.49) Estimate

Reported cumulative MMR rate of 44% (16 of 36) by 24 weeks with 26% (7 of 27) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent Phase 1 trials of approved BCR::ABL1 TKIs
ELVN-001 continues to demonstrate a favorable safety and tolerability profile across all dose levels with 74 patients enrolled and a median treatment duration of ~26 weeks at cutoff
Presentation at EHA will include updated data with additional patients and longer treatment duration
Enliven will host a webcast and conference call on June 13 at 1:30 p.m. ET
BOULDER, Colo., May 14, 2025 /PRNewswire/ --&nbsp;Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVN#NASDAQ">ELVN</a>), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced updated, positive data from the Phase 1 ENABLE clinical trial evaluating ELVN-001 in patients with chronic myeloid leukemia (CML) in an abstract accepted for an oral presentation at the European Hematology Association (EHA) 2025 Congress taking place June 12-15 in Milan, Italy, and virtually. Updated data will be presented during an oral presentation at the conference on Friday, June 13, at 5 p.m. CEST/11 a.m. ET. Enliven management will host a webcast and conference call to discuss the data on Friday, June 13, at 7:30 p.m. CEST/1:30 p.m. ET.

Enliven Therapeutics Announces Updated Data From Phase 1 ENABLE Clinical Trial Evaluating ELVN-001 In Patients With CML In Abstract Accepted For Oral Presentation At EHA 2025 Congress

U.S. stock futures were higher this morning, with the Dow futures gaining more than 900 points on Tuesday.
Shares of The Greenbrier Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GBX#NYSE">GBX</a>) fell sharply in today's pre-market trading as the company <a href="https://www.benzinga.com/quote/GBX/earnings">posted downbeat results for its second quarter.</a>
Greenbrier reported quarterly earnings of $1.56 per share which missed the analyst consensus estimate of $1.78 per share. The company reported quarterly sales of $762.100 million which missed the analyst consensus estimate of $898.530 million.
Greenbrier shares dipped 3.9% to $43.00 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>CVRx, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVRX#NASDAQ">CVRX</a>) shares dipped 29.8% to $8.10 in today's pre-market trading after the company reported preliminary first quarter 2025 financial results.</li>
<li>Collective Mining Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNL#NYSE">CNL</a>) declined 12.2% to $7.31 in pre-market trading.</li>
<li>InnovAge Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INNV#NASDAQ">INNV</a>) fell 11.2% to $2.70 in pre-market trading after gaining over 7% on Monday.</li>
<li>PureTech Health plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTC#NASDAQ">PRTC</a>) dipped 11% to $16.02 in pre-market trading.</li>
<li>Emerald Holding, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EEX#NYSE">EEX</a>) fell 7.5% to $3.2100 in pre-market trading.</li>
<li>Celcuity Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELC#NASDAQ">CELC</a>) dipped 7.1% to $8.51 in pre-market trading. Celcuity recently reported a year-over-year decrease in fourth-quarter EPS results.</li>
<li>RPM International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RPM#NYSE">RPM</a>) fell 5.9% to $100.40 in pre-market trading following weaker-than-expected quarterly results.</li>
<li>Maze Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAZE#NASDAQ">MAZE</a>) fell 4.5% to $8.52 in pre-market trading.</li>
<li>Enliven Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVN#NASDAQ">ELVN</a>) declined 3.8% to $17.20 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44678688/dow-falls-for-3rd-session-amid-trumps-tariff-threats-as-apple-tesla-decline-greed-index-remains-in-extreme-fear-zone">Dow Falls For 3rd Session Amid Trump&#8217;s Tariff Threats As Apple, Tesla Decline: Greed Index Remains In &#8216;Extreme Fear&#8217; Zone</a> </li>
</ul>
Photo via Shutterstock

CELC

CVRX

INNV

MAZE

PRTC

Greenbrier, RPM International, CVRx And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

HC Wainwright &amp; Co. analyst Robert Burns maintains Enliven Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVN#NASDAQ">ELVN</a>) with a Buy and raises the price target from $37 to $39.

HC Wainwright & Co. Maintains Buy on Enliven Therapeutics, Raises Price Target to $39

Enliven Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVN#NASDAQ">ELVN</a>) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of $(0.52) by 11.54 percent. This is a 2.13 percent increase over losses of $(0.47) per share from the same period last year.

Earnings Beats

Enliven Therapeutics Q4 2024 GAAP EPS $(0.46) Beats $(0.52) Estimate

BTIG analyst Justin Zelin initiates coverage on Enliven Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVN#NASDAQ">ELVN</a>) with a Buy rating and announces Price Target of $42.

BTIG Initiates Coverage On Enliven Therapeutics with Buy Rating, Announces Price Target of $42

Baird analyst Colleen Kusy maintains Enliven Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVN#NASDAQ">ELVN</a>) with a Outperform and raises the price target from $32 to $40.

Baird Maintains Outperform on Enliven Therapeutics, Raises Price Target to $40

Enliven Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVN#NASDAQ">ELVN</a>) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.49) by 2.04 percent.

Enliven Therapeutics Q3 2024 GAAP EPS $(0.48) Beats $(0.49) Estimate

Press Releases

Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting

Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML and Oral Presentation at the EHA 2025 Congress

Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update

Enliven Therapeutics to Present at Upcoming Investor Conferences

Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress

Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Enliven Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Comments

Enliven Therapeutics

Actualités

Dernières nouvelles pour Enliven Therapeutics (NASDAQ:ELVN) Stock

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL